Press Releases

See the latest from ProtoKinetix

Review our press releases for information about our current research, recent findings and key milestones. If you want to follow along our journey of cell survival, subscribe to our newsletter so you never miss an update.
Therapeutic application:
Year:
Sort By:
Jan 06, 2020
Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) announces that ITR Laboratories of Montreal have run multiple tests on eye irritation at maximum concentration of AAGP® and to […]
Dec 19, 2019
Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) announces the completion of an in vivo study to assess the effect of AAGP® on the long term survival and […]
Nov 22, 2019
Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) announces the initiation of a program testing AAGP®, to develop a potential therapy to treat Dry Eye Disease (DED). AAGP® […]
Nov 06, 2019
Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) is pleased to provide the following updates regarding upcoming news in key areas. Current projects updates are expected from the […]
Aug 23, 2019
ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) updates shareholders regarding ongoing 3rd stage testing of retinal cell replacement therapy at the University of British Columbia. As previously reported, the […]
Jul 09, 2019
Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) has reached the mid-point of 3rd stage of testing in retinal cell replacement therapy at the University of British Columbia. […]
Request More Information

Talk to a member of the ProtoKinetix team to learn more about our research and results.

Picture of a molecule
Picture of a molecule